The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: The Body Protection Compound Revolutionizing Regenerative Medicine 503Pharma FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The Peptide Ban Is Ending: FDA Peptides Explained Apple Podcasts